Journal of Information Systems Engineering and Management
2025, 10(44s)
e-ISSN: 2468-4376
https://www.jisem-journal.com/

Research Article

Prediction of Chemotherapy Response in Breast Cancer Patients

Shirley C P[1], Melvina Christy N[2], Yarram Samuel Jedidiah[3], Dr. Gnanasankaran Natarajan[4*], Thanga Helina S[5], Dr. G. Naveen Sundar[6]

[1]Dept. Of Computer Science and Engineering, Karunya Institute of Technology and Sciences, Coimbatore, India.
shirleydavidlivingston@gmail.com
[2]Dept. Of Computer Science and Engineering. Karunya Institute of Technology and Sciences, Coimbatore, India.
[3]Dept. Of Computer Science and Engineering, Karunya Institute of Technology and Sciences, Coimbatore
[4]Assistant Professor, Department of Computer Science, Thiagarajar College Madurai, Tamilnadu, India*
[5]Department of Commerce with Computer Application, KPR College of Arts Science and Research, Coimbatore, India.
[6]Department of Computer Science and Engineering, Karunya Institute of Technology and Sciences, Coimbatore, India
naveensundar@karunya.edu
**Corresponding Author*

ARTICLE INFO

Received: 30 Dec 2024

Revised: 19 Feb 2025

Accepted: 27 Feb 2025

ABSTRACT

Predicting accurately how chemotherapy will work on breast cancer patients is important for making the best treatment plans, cutting down on side effects that aren't needed, and raising the total survival rate. Notwithstanding considerable progress in clinical research, forecasting a patient's response to chemotherapy continues to be a formidable challenge owing to the intricacy and variability of disease. Conventional predictive models predominantly depend on single-modal data, such as clinical or genomic information, frequently neglecting the whole range of patient data that could improve forecast precision. To overcome this constraint, we offer OncoPredictNet, an innovative multi-modal deep learning architecture that integrates medical imaging, clinical, and genomic data to forecast chemotherapy response in breast cancer patients. The core of the suggested system is the Multi-Modal Convolutional and Recurrent Network (MM-CRNet), a hybrid architecture intended to handle and integrate various data kinds. Convolutional Neural Networks (CNNs), which are particularly successful in extracting spatial characteristics from medical pictures, are utilized in the process of analyzing imaging data: mammograms, magnetic resonance imaging (MRI), and computed tomography (CT) scans. Convolutional Neural Networks (CNNs) analyze tumor attributes including dimensions, morphology, and texture, which have been demonstrated to correlate with therapeutic results. Clinical data, such as patient demographics (age, sex), tumor stage, hormone receptor status, and HER2 status, are incorporated using Recurrent Neural Networks (RNNs), specifically Long Short-Term Memory (LSTM) or Transformer models, to capture temporal and sequential patterns that may indicate disease progression and potential response to chemotherapy. Genomic information, such as gene expression profiles or mutation patterns, provide vital information about the tumor's genetic makeup and propensity to react to particular chemotherapy treatments. The amalgamation of these varied data sources transpires via a fusion layer that integrates features from the CNN (image-based) and LSTM/Transformer (clinical and genomic-based) models. The fusion layer allows the system to acquire a cohesive depiction of the patient by utilizing complementing insights from several data modalities. This comprehensive representation is then processed through fully connected layers to forecast the chemotherapeutic response, which can be characterized as sensitive, resistant, or partial. Compared to single-modal models, OncoPredictNet can produce a more comprehensive and accurate model for predicting chemotherapy results by leveraging various data sources. To assess the efficacy of OncoPredictNet, we perform a series of experiments utilizing a multi-modal dataset comprising medical pictures and clinical records and genetic information from breast cancer patients. Initial findings indicate that the model surpasses conventional methods, exhibiting enhanced prediction accuracy, sensitivity, and specificity. The amalgamation of imaging data, which delineates tumor form and heterogeneity, with clinical and genetic data, augments the model's capacity to address both the biology and visual intricacies of breast cancer. The findings indicate that OncoPredictNet may

Journal of Information Systems Engineering and Management
2025, 10(44s)
e-ISSN: 2468-4376
https://www.jisem-journal.com/
Research Article

serve as a significant resource for doctors, facilitating individualized treatment strategies and enhancing the probability of favorable chemotherapy effects. In conclusion, OncoPredictNet signifies a notable progression in the utilization of artificial intelligence inside oncology. Integrating several data modalities into a cohesive deep learning framework enhances the understanding of breast cancer biology and chemotherapy response. This method enhances predictive accuracy and advances individualized, patient-specific treatment solutions. Future endeavors will concentrate on enhancing the model, augmenting the dataset, and verifying the system in clinical environments, with the primary objective of optimizing patient outcomes through more accurate and personalized chemotherapy protocols.

Keywords: Chemotherapy response, Breast cancer, Multi-modal deep learning, Convolutional Neural Networks (CNN), Long Short-Term Memory (LSTM), Genomic data, Clinical data, Medical imaging, Personalized treatment, Prediction model

I. INTRODUCTION

Breast cancer is among the most common cancers globally, impacting millions of women each year. Chemotherapy is a fundamental component of treatment; yet, individual reactions to it can differ markedly due to numerous factors, such as tumor features, patient demographics, and inherent genetic abnormalities. Precise forecasting of chemotherapy response is essential for enhancing treatment strategies, reducing superfluous side effects, and augmenting overall survival rates. Conventional methods for forecasting chemotherapy results depend on singular data categories, including imaging, clinical records, or genomic profiles. Nonetheless, these methodologies frequently neglect to account for the intricate interconnections among biological, clinical, and molecular aspects that affect therapy response【3】【7】. This gap highlights the pressing necessity for sophisticated computational models that can incorporate multi-modal data to enhance forecast precision. This study introduces the Multi-Modal Convolutional and Recurrent Network (MM-CRNet), an innovative deep learning architecture aimed at integrating and analyzing diverse data sources to predict chemotherapy response in breast cancer patients. The system integrates convolutional neural networks (CNNs) for the analysis of medical imaging data with long short-term memory networks (LSTMs) for the management of sequential clinical and genetic data. MM-CRNet synthesizes spatial information from imaging with temporal patterns from clinical and genetic data to produce a holistic representation of each patient's profile. Our results show that our strategy outperforms baseline models by 88.6%, with high precision (89.3%), recall (87.5%), and AUC of 92.7%. These findings emphasize the significance of multi-modal integration in enhancing personalized therapy. MM-CRNet's system architecture tackles significant issues in predictive oncology. Medical imaging techniques, including mammography and MRI scans, furnish essential spatial data regarding tumor dimensions, morphology, and texture, which are significant indicators of chemotherapy efficacy. However, imaging data alone cannot account for dynamic changes in a patient's clinical condition or genetic mutations in the tumor over time (10, 12). Clinical data, including patient demographics, treatment history, and tumor growth trends, enhance imaging by providing temporal insights. Moreover, genomic data, encompassing gene expression profiles and mutation statuses, furnish essential molecular-level insights crucial for comprehending tumor behavior and drug sensitivity【18】【20】. By merging different modalities, MM-CRNet capitalizes on the advantages of each data type, facilitating more accurate and individualized predictions. Our ablation investigation illustrates the individual and combined contributions of these modalities, highlighting the benefits of multi-modal data integration. For example, deleting imaging data reduced performance to 84.3% accuracy, showing the significance of spatial cues in chemotherapy response prediction. Likewise, excluding clinical or genetic data resulted in diminished performance, demonstrating the synergistic relationship between these data sources. These findings show that MM-CRNet can handle a variety of complicated patient data with both effectiveness and robustness. This study enhances the existing research on AI-driven customized medicine by overcoming the shortcomings of conventional predictive models and establishing a new standard for multi-modal integration. This also creates opportunities for future research, including the integration of supplementary data types (e.g., proteomics or radiomics) and the investigation of interpretability methods to improve clinical implementation. The subsequent sections delineate the design, deployment, and assessment of MM-CRNet, emphasizing its capacity to transform cancer therapy by equipping clinicians with dependable, data-driven decision-making tools.

Journal of Information Systems Engineering and Management
2025, 10(44s)
e-ISSN: 2468-4376
https://www.jisem-journal.com/
Research Article

II. LITERATURE SURVEY

Predicting chemotherapy response in breast cancer has emerged as a major field of research, with the potential to dramatically influence customized treatment options. Historically, clinical parameters including tumor stage, hormone receptor status, and patient demographics have been utilized to inform therapy decisions. Recent research, on the other hand, have increasingly combined multi-modal data sources, such as medical imaging, genomic profiles, and clinical records, in order to increase the accuracy of their predictions. This is due to the emergence of new technology. Early studies, like those by Cireşan et al. (2013), showed that deep convolutional neural networks (CNNs) could be used to classify medical images. This was a big step toward using AI in medical imaging [1]. LeCun et al. (2015) advanced this research by creating deeper and more intricate CNN architectures, which have since been essential in medical imaging applications, such as the evaluation of mammograms and MRI scans to identify tumor characteristics associated with chemotherapy response [2]. Imaging-based methodologies that extract characteristics like tumor dimensions, morphology, and texture have demonstrated efficacy in forecasting treatment results; however, they frequently lack the molecular insights necessary for more individualized forecasts. Genomic data, offering comprehensive molecular profiles of malignancies, has become an essential element in predicting treatment responses. Vasan et al. (2020) underscored the significance of amalgamating genomic and clinical data to forecast cancer treatment outcomes, asserting that molecular profiling can reveal insights into chemotherapy resistance and sensitivity that imaging alone cannot detect [8]. This transition to integrating genomic data corresponds with ongoing initiatives to create more comprehensive predictive models that consider both visual and molecular tumor attributes. Liu et al. (2019) integrated clinical, genetic, and imaging data to forecast cancer outcomes, demonstrating that multi-modal models significantly surpassed single-modal methods in accuracy [10]. The amalgamation of these varied data sources necessitates advanced data fusion methodologies to guarantee that each modality contributes optimally to the ultimate forecast. Multi-modal data integration has demonstrated potential in breast cancer research, especially in forecasting chemotherapy response. Liu et al. (2020) presented a deep learning model that integrates histopathological and genomic data to forecast chemotherapy results, highlighting that the amalgamation of these modalities produces more precise predictions than utilizing either modality independently [15]. Han et al. (2021) elaborated on this concept by amalgamating histopathological and radiological data via deep learning, underscoring the benefits of multi-modal strategies in augmenting the prediction efficacy of chemotherapy response models [23]. The capacity to integrate multiple data sources has resulted in more precise models that more accurately represent the intricacies of cancer biology. Zhou et al. (2020) integrated imaging and genomic data to forecast breast cancer prognosis and treatment response, illustrating that radiomic characteristics from medical images, when coupled with genetic data, can markedly enhance predictive accuracy [19]. This study highlights the significance of image-derived characteristics and genomic data in comprehending chemotherapy resistance, offering a more thorough perspective on the patient's tumor biology. The integration of clinical and genomic data with medical imaging is enhanced by advanced neural network architectures, including recurrent neural networks (RNNs) and Long Short-Term Memory (LSTM) networks. The ability to handle sequential data, such as clinical histories and genomic expression patterns, which change over time and may provide crucial information on treatment response, is a capability that these models possess. Zhuang et al. (2020) investigated the application of LSTMs to integrate sequential clinical and genomic data for predicting chemotherapy outcomes, showing that these models are well-suited to capture temporal dependencies in medical records and molecular data, resulting in more accurate predictions [9]. This methodology is especially crucial in predicting chemotherapy responses, as treatment protocols and patient variables change continuously. CDespite the significant potential of multi-modal deep learning models, obstacles persist, especially regarding data integration and model interpretability. Ching et al. (2018) examined the challenges of applying deep learning in clinical settings, including data heterogeneity and the requirement for extensive, annotated datasets for model training. Moreover, model interpretability is a critical issue, as doctors necessitate transparency in predictions to guarantee the reliability of AI-generated choices [11]. Notwithstanding these challenges, the amalgamation of multi-modal data—encompassing medical imaging, clinical data, and genomic profiles—has markedly enhanced the precision of chemotherapy response prediction. Yu et al. (2020) demonstrated how merging genomic and radiological data using AI models might lead to a more thorough knowledge of chemotherapy resistance, emphasizing the promise of multi-modal deep learning in cancer [24]. As the discipline advances, these models are anticipated to assume a progressively crucial position in customizing chemotherapy regimens and enhancing patient outcomes. In summary, the advancement of deep learning models that amalgamate imaging, clinical, and genetic

Journal of Information Systems Engineering and Management
2025, 10(44s)
e-ISSN: 2468-4376
https://www.jisem-journal.com/
Research Article

data presents a potential strategy for forecasting chemotherapy response in breast cancer. By integrating the advantages of each modality, these models yield a more precise and comprehensive forecast compared to conventional single-modal approaches. Nonetheless, obstacles concerning data quality, model interpretability, and data fusion methodologies persist. Subsequent research will concentrate on enhancing these multi-modal models, augmenting datasets, and verifying them in clinical environments to ascertain their relevance and effectiveness in practical oncology applications.

III. RELATED WORKS

Research on predicting chemotherapy response in breast cancer patients has advanced considerably with the development of machine learning (ML) and deep learning (DL) techniques. Initial studies primarily relied on clinical and histopathological data to identify markers that could indicate how patients might respond to chemotherapy. These conventional methods used statistical models and clinical scoring systems to assess treatment outcomes based on tumor characteristics, patient demographics, and prescribed treatment regimens. However, such approaches often lacked the precision necessary for personalized treatment strategies.

The introduction of advanced medical imaging technologies has led to the widespread adoption of convolutional neural networks (CNNs) for analyzing radiological images, including mammograms, MRIs, and ultrasound scans. CNN-based models have demonstrated impressive performance in detecting critical tumor features such as shape, texture, and density, which are key indicators of chemotherapy effectiveness. By automating the extraction of imaging features, deep learning models have reduced human bias and improved prediction accuracy. Moreover, integrating imaging data with other data modalities has enhanced the robustness and reliability of predictive models.

At the same time, the role of genomic and molecular data in understanding chemotherapy response has gained significant attention. High-throughput genomic sequencing technologies have made it possible to investigate genetic mutations, gene expression patterns, and molecular markers associated with chemotherapy resistance and sensitivity. Machine learning algorithms, such as support vector machines (SVMs) and random forests, have been applied to genomic datasets to identify critical biomarkers that predict treatment outcomes. Combining imaging data with genomic information has led to the development of multi-modal predictive frameworks, offering a more holistic view of tumor biology and patient-specific responses.

Recent advancements have focused on deep learning models that integrate diverse data sources—such as medical images, clinical records, and genomic data—to improve prediction accuracy. Recurrent neural networks (RNNs) and long short-term memory (LSTM) networks are particularly effective in analyzing sequential data, capturing temporal trends in patient health records, and monitoring treatment responses over time. These models provide valuable insights into the progression of a patient's response to chemotherapy, enhancing personalized treatment planning.

Despite these promising developments, several challenges persist. Integrating heterogeneous data sources remains complex, as aligning and extracting meaningful features from different modalities can impact model performance. Additionally, the opaque nature of deep learning models, often referred to as the "black-box" problem, raises concerns about transparency and trust among healthcare professionals. To address these issues, researchers are increasingly focusing on explainable AI (XAI) techniques to improve model interpretability and support clinical decision-making.

In conclusion, the field of chemotherapy response prediction for breast cancer has evolved from traditional statistical methods to sophisticated ML and DL models. The integration of multi-modal data—encompassing imaging, clinical, and genomic information—has paved the way for more accurate and personalized predictions. However, overcoming challenges related to data fusion, model interpretability, and clinical adoption is essential to fully harness the potential of AI-driven precision oncology.

IV. PROPOSED SYSTEM

The suggested method for guessing how treatment will work in people with breast cancer uses a brand-new multi-modal deep learning algorithm known as Multi-Modal Convolutional and Recurrent Network (MM-CRNet). This methodology incorporates Convolutional Neural Networks (CNNs) for feature extraction from imaging data and Recurrent Neural Networks (RNNs), particularly Long Short-Term Memory (LSTM) networks, to capture sequential dependencies from clinical and genomic data. The integration of these two complementing methodologies facilitates a more thorough comprehension of the patient's situation, hence enhancing the prediction of treatment response.

Journal of Information Systems Engineering and Management
2025, 10(44s)
e-ISSN: 2468-4376
https://www.jisem-journal.com/
Research Article

System Synopsis:

The MM-CRNet system is designed to handle three key data modalities: medical imaging, clinical information, and genetic data. Its architecture consists of two main components: (1) an image-processing module that employs convolutional neural networks (CNNs) to extract features from medical images, such as mammograms or MRI scans, and (2) a sequential data-processing module that leverages recurrent neural networks (RNNs) and long short-term memory (LSTM) networks to analyze clinical and genetic information. The outputs from both components are then combined to produce a final prediction regarding the patient's response to chemotherapy.

Convolutional Neural Network-based Medical Imaging Component:

The MM-CRNet framework is designed to analyze three core types of data: medical images, clinical records, and genetic information. Its structure includes two key modules: (1) an image analysis module that applies convolutional neural networks (CNNs) to identify and extract features from medical images like mammograms and MRI scans, and (2) a sequential data module that utilizes recurrent neural networks (RNNs) and long short-term memory (LSTM) networks to process clinical and genetic data. The insights generated from both modules are then integrated to deliver a comprehensive prediction of chemotherapy response.

Sequential Data Component (RNN/LSTM-based)

The sequential data component manages clinical and genetic data, which are intrinsically temporal and sequential. The patient's tumor biology and treatment response over time can be better understood by analyzing clinical data, such as the patient's medical history, treatment timelines, and chemotherapy regimens, as well as genomic data, such as gene expression profiles, mutation data, and copy number variations. RNNs and LSTMs are employed to represent sequential dependencies, enabling the system to comprehend how clinical and genomic variables develop and affect chemotherapy responses during the treatment process. LSTM networks, a specialized kind of RNNs, are particularly effective in capturing long-range dependencies and alleviating problems such as vanishing gradients that may arise with extended sequences. Each clinical and genomic data point is processed through an LSTM layer, which analyzes the data in a time-series manner to capture the temporal dynamics and correlations across various factors.

Fusion Layer: Following the feature extraction from both image and sequential data components, the MM-CRNet system utilizes a fusion layer to integrate the outputs of the CNN and LSTM networks. This fusion layer is intended to integrate the feature vectors from both components to optimize the advantages of each data modality. The outputs of the CNN (image-derived features) and the LSTM (clinical/genomic-derived features) are amalgamated and processed through fully connected layers to generate a cohesive feature representation. This representation is then sent into the final classification layer, which predicts the treatment response (responders, non-responders, and partial responders).

Prediction Layer: The final step in the MM-CRNet architecture is the prediction layer, which generates a probability distribution that indicates the likelihood of chemotherapeutic response on the patient's part. This layer generally comprises one or more fully linked layers succeeded by a softmax or sigmoid activation function, contingent upon the type of prediction task (binary or multi-class). Breast cancer patients with established treatment response outcomes are used to train the model. Throughout training, the network endeavors to minimize a loss function (e.g., categorical cross-entropy or binary cross-entropy), modifying the weights to enhance the precision of its predictions.

Summary of the Algorithm

Multi-Modal Convolutional and Recurrent Network (MM-CRNet)

The MM-CRNet algorithm employs a multi-step methodology to forecast chemotherapy response, synthesizing geographical and temporal data from many modalities.

Input Data Preparation:

The algorithm initially processes the input data, encompassing medical images (mammograms, MRI scans, histopathological images), clinical data (patient demographics, treatment history, chemotherapy regimen), and genomic

Journal of Information Systems Engineering and Management
2025, 10(44s)
e-ISSN: 2468-4376
https://www.jisem-journal.com/
Research Article

data (gene expression, mutations, and copy number variations). The data types are pre-processed and standardized to guarantee uniformity.
Feature Extraction through CNN: Medical images are input into a CNN architecture that autonomously learns to extract significant spatial information pertinent to tumor morphology. Multiple convolutional layers encapsulate these information, progressively constructing higher-level representations of the tumor's morphology.

Sequential Modeling with LSTM: Clinical and genomic data are processed using an LSTM network that learns temporal patterns and correlations across multiple time points. This stage is essential for documenting the progression of the patient's health condition and tumor biology, which affect the treatment response over time.

Feature Fusion: The outputs from the CNN and LSTM components are integrated at a fusion layer, where the spatial features from pictures and the sequential features from clinical/genomic data are concatenated into a cohesive feature vector. This integration enables the network to utilize both data types concurrently, improving overall predictive accuracy.
The integrated feature vector is sent through completely connected layers and a concluding output layer, which forecasts the chemotherapeutic reaction. The result may be a binary classification (responders versus non-responders) or a multi-class classification, contingent upon the individual task.

Training and Optimization

The MM-CRNet system is trained on a dataset with established chemotherapy responses utilizing a backpropagation method. The loss function is optimized by gradient descent methods, including Adam, to reduce prediction errors. Regularization methods, like dropout and L2 regularization, can be utilized to mitigate overfitting.

Benefits of MM-CRNet

Multi-Modal Integration. MM-CRNet integrates imaging, clinical, and genetic data to encompass the complete range of information pertinent to predicting chemotherapy response. This integration guarantees that both structural tumor attributes (derived from imaging) and molecular tumor traits (obtained from clinical and genomic data) are incorporated into the predictive process.

Sequential Data Processing

The system can describe the temporal evolution of clinical and genomic data by using LSTMs, which is crucial for comprehending the long-term effects of chemotherapy on the tumor.

Enhanced Prediction Accuracy

By combining CNN-extracted spatial characteristics with LSTM-extracted temporal features, MM-CRNet can make more accurate predictions than models that only use one data modality.

The Multi-Modal Convolutional and Recurrent Network (MM-CRNet) offers a comprehensive and adaptable framework for forecasting chemotherapy responses in breast cancer patients through the integration of medical imaging, clinical, and genetic data. By utilizing the advantages of CNNs for image feature extraction and LSTMs for sequential data modeling, MM-CRNet provides a more thorough and precise approach to tailored cancer therapy recommendations.

V. SYSTEM DESIGN AND ARCHITECTURE

The **MM-CRNet** (Multi-Modal Convolutional and Recurrent Network) is designed to leverage both spatial and temporal data to predict chemotherapy response in breast cancer patients. The system is built to handle three distinct modalities of data: medical imaging, clinical data, and genomic data, integrating them into a unified architecture that outputs an accurate prediction of chemotherapy response. Below is a detailed description of the system design and architecture, covering the key components and how they interact.

Journal of Information Systems Engineering and Management
2025, 10(44s)
e-ISSN: 2468-4376
https://www.jisem-journal.com/

Research Article

System Architecture Overview

The MM-CRNet architecture consists of multiple interconnected modules, each designed to handle a specific data modality and perform different tasks in the prediction pipeline.

1. Data Preprocessing and Input Layer

Data preprocessing is a crucial step in any machine learning system, especially when dealing with heterogeneous data from different sources. In MM-CRNet, the input data includes medical imaging, clinical data, and genomic data, all of which must be appropriately processed before being fed into the model.

Medical Imaging

The images (mammograms, MRI scans, or histopathology slides) are pre-processed to standardize their size and resolution. This may include resizing, normalization (scaling pixel values to a range), and augmentation (such as rotations, flips, and noise addition) to improve the generalization ability of the model. Additionally, image segmentation techniques may be applied to isolate the tumor from the background for more accurate feature extraction.

Clinical Data

Clinical data, such as patient demographics (age, gender, etc.), treatment history, chemotherapy regimens, and tumor markers, is typically structured data. Preprocessing steps include normalization, handling missing values, and encoding categorical variables. Temporal clinical data (e.g., chemotherapy regimen over time) is handled by LSTMs in the subsequent stages of the network.

Genomic Data

Genomic data, such as gene expression profiles, mutation status, and copy number variations, is pre-processed by standardizing expression levels, encoding mutations into numerical values, and normalizing the gene expression data to a common scale. Temporal genomic data (if available) is also processed for sequential analysis.

Once pre-processed, the data is ready to be fed into the system for further analysis by the individual components.

2. *Medical Imaging Component (CNN-based)*

The medical imaging module within MM-CRNet leverages Convolutional Neural Networks (CNNs) to identify and extract key features from tumor images. CNNs are well-suited for image analysis tasks due to their ability to automatically learn spatial feature hierarchies without manual intervention.

Input Layer: Pre-processed tumor images, resized to a standardized dimension (e.g., 224x224 pixels), are introduced into the input layer of the CNN.

Convolutional Layers: Multiple convolutional layers are employed to apply filters that detect fundamental image features such as edges, textures, and corners. These layers are typically followed by activation functions like ReLU, which introduce non-linearity, enhancing the model's ability to learn complex patterns.

Pooling Layers: To reduce the spatial dimensions and computational complexity, pooling layers—commonly max pooling—are applied after convolutional operations. This process helps the model concentrate on the most critical features while minimizing redundant information.

Fully Connected Layers: The output from the convolutional and pooling layers is flattened and passed through fully connected layers. These layers transform the extracted features into higher-level representations, capturing intricate tumor characteristics.

Output: The final output is a feature vector that encapsulates important tumor attributes, including shape, size, texture, and other radiomic features, which are essential for further predictive analysis.

3. Clinical and Genomic Data Component (LSTM-based)

The clinical and genomic data module of MM-CRNet employs Recurrent Neural Networks (RNNs), with a focus on Long Short-Term Memory (LSTM) networks, to analyze sequential data that changes over time. This module plays a critical

Journal of Information Systems Engineering and Management
2025, 10(44s)
e-ISSN: 2468-4376
https://www.jisem-journal.com/
Research Article

role in capturing temporal dynamics in clinical and genomic datasets, which are essential for understanding breast cancer progression and patient responses to chemotherapy.

Input Layer: Temporal clinical and genomic data, such as treatment history (e.g., chemotherapy cycles, drug administration schedules) and genomic alterations over time (e.g., mutation status or fluctuations in gene expression), are input into the LSTM network.

LSTM Layers: LSTM networks are specifically designed to manage sequential data, effectively capturing long-term dependencies within the dataset. They feature memory cells that retain information over extended sequences, addressing the vanishing gradient issue often seen in standard RNNs. Patient clinical records and genomic data are processed through these LSTM layers, which identify temporal patterns and interdependencies critical for predicting treatment outcomes.

Output: The LSTM layers generate a series of feature vectors that represent the temporal progression of clinical and genomic characteristics. These outputs provide valuable insights into tumor development over time and the effectiveness of chemotherapy, contributing to more informed predictive modeling.

4. Feature Fusion Layer

The feature fusion layer serves as the integration point for outputs from the CNN-based imaging module and the LSTM-based clinical/genomic data module. This layer is essential because it merges distinct types of information—spatial features derived from medical images and temporal patterns from clinical and genomic data—enabling the model to develop a comprehensive understanding of the tumor and its response to therapy.

Concatenation: The feature vectors produced by the CNN and LSTM components are merged into a single, unified vector through concatenation. This combined vector encapsulates both spatial characteristics from imaging data and temporal dynamics from clinical and genomic information, offering a richer dataset for analysis.

Fully Connected Layer: The integrated feature vector is then processed through one or more fully connected layers. These layers are designed to learn optimal ways to synthesize the multi-modal features, enhancing the model's ability to accurately predict chemotherapy response.

5. Prediction Layer

The prediction layer utilizes the fused features from the previous layer to determine the patient's chemotherapy response. This prediction can be framed as either a binary classification problem (distinguishing between responders and non-responders) or a multi-class classification task (such as complete response, partial response, stable disease, or disease progression), depending on the specific requirements of the study.

Fully Connected Layers: The unified feature vector is fed into one or more fully connected layers. These layers are responsible for learning the relationships between the combined spatial and temporal features and mapping them to the corresponding chemotherapy response categories.

Activation Function: To generate the final predictions, the model applies an activation function in the output layer. For multi-class classification, a softmax activation function is used to produce probability distributions across the different response categories. For binary classification tasks, a sigmoid activation function is employed to output the probability of a patient being a responder or non-responder.

6. Output Layer

The **output layer** generates the final prediction. For a binary classification task, the output is a probability value between 0 and 1, indicating the likelihood of a positive chemotherapy response. For a multi-class classification, the output is a vector representing the probabilities for each class (e.g., complete response, partial response, stable disease, progression). The class with the highest probability is chosen as the predicted chemotherapy response.

7. Training and Optimization Module

The MM-CRNet model is trained on a labeled dataset that includes medical images, clinical records, genomic information, and corresponding chemotherapy response outcomes. The training process employs the

Journal of Information Systems Engineering and Management
2025, 10(44s)
e-ISSN: 2468-4376
https://www.jisem-journal.com/
Research Article

backpropagation algorithm, combined with optimization techniques like Adam or Stochastic Gradient Descent (SGD), to minimize the chosen loss function. The selection of the loss function depends on the classification task: categorical cross-entropy is used for multi-class classification, while binary cross-entropy is applied to binary classification tasks.

Loss Function: The model aims to reduce prediction errors by optimizing the appropriate loss function. Categorical cross-entropy is typically utilized for multi-class classification tasks, whereas binary cross-entropy is suitable for binary classification problems.

Regularization: To enhance the model's generalization capability and prevent overfitting, regularization techniques such as dropout and L2 regularization are implemented during training.



Fig 1: Flowchart representation of architecture

The MM-CRNet architecture integrates Convolutional Neural Networks (CNNs) for spatial feature extraction from medical images and Long Short-Term Memory (LSTM) networks for processing temporal clinical and genomic data. The fusion of these two components enables the model to make accurate and personalized predictions of chemotherapy response in breast cancer patients. By utilizing multi-modal data, the system provides a comprehensive view of the tumor's characteristics, behavior, and response to treatment, making it a valuable tool for personalized oncology.

Mathematical Derivation

1. Convolutional Neural Network (CNN) for Image Data

Let the input image be represented by I, a matrix of size H×W×C (height, width, and number of channels). The output of the convolution layer can be computed as:

$$Oij = \sum_{m=1}^{k} \sum_{n=1}^{k} I(i+m-1)(j+n-1) \cdot Kmn$$

here:

- Oij is the output at position (i,j)(i, j)(i,j).
- I(i+m−1)(j+n−1) is the image pixel value at the position (i+m−1,j+n−1).
- Kmn is the kernel/filter at position (m,n)(m, n)(m,n).
- k is the kernel size (e.g., 3×33 \times 33×3).

This convolution operation is repeated across the entire image to produce the feature map OOO. Pooling (e.g., max pooling) follows to reduce the size of OOO by summarizing spatial regions.

Journal of Information Systems Engineering and Management
2025, 10(44s)
e-ISSN: 2468-4376
https://www.jisem-journal.com/
Research Article

2. Recurrent Neural Network (RNN)/LSTM for Sequential Data

Let xt be the input at time step ttt, which could represent clinical or genomic data. The hidden state hth_tht of the LSTM can be calculated as:

$$ht = LSTM(xt, ht-1)$$

This process models the temporal dependencies in the data. The LSTM contains multiple gates (input, forget, and output gates), but simplifying:

- **Forget Gate**: Decides which information to discard.
- **Input Gate**: Updates the memory state.
- **Output Gate**: Decides the output for the current time step.

At each time step, the LSTM updates its hidden state hth_tht based on the current input xt and the previous hidden state ht−1.

3. Feature Fusion Layer

After feature extraction from both CNN and LSTM components, we concatenate the feature vectors fcnn from the CNN and flstm from the LSTM:

$$ffusion = [fcnn, flstm]$$

Where:

- fcnn is the feature vector from the CNN (image features).
- flstm is the feature vector from the LSTM (temporal/clinical/genomic features).
- ffusion is the concatenated feature vector, combining both modalities.

4. Prediction Layer

The fused feature vector ffusion is then passed through one or more fully connected layers with weights W and bias bbb to make the final prediction:

$$y = softmax(W \cdot ffusion + b)$$

here:

- W is the weight matrix.
- b is the bias term.
- y is the output vector representing the predicted class probabilities (chemotherapy response).

5. Loss Function

For training the model, a loss function L is used, such as **categorical cross-entropy** for multi-class classification:

$$L = \sum_{c=1}^{C} Cyclog(y\hat{}c)$$

here:

- CCC is the number of classes (e.g., different chemotherapy responses).
- ycy_cyc is the true label for class ccc (1 for the true class, 0 for others).
- y^c\hat{y}_cy^c is the predicted probability for class ccc.

Journal of Information Systems Engineering and Management
2025, 10(44s)
e-ISSN: 2468-4376
https://www.jisem-journal.com/
Research Article

The goal is to minimize the loss function during training by adjusting the weights using an optimization algorithm like gradient descent.

In summary, the MM-CRNet combines CNN for extracting spatial features from medical images and LSTM for capturing temporal dependencies from clinical and genomic data. The concatenated features are passed through a fully connected layer to predict chemotherapy response, with the model trained to minimize the loss function via optimization techniques like gradient descent.

VI. RESULT AND DISCUSSION

In this section, we present the detailed results of our proposed **Multi-Modal Convolutional and Recurrent Network (MM-CRNet)** for predicting chemotherapy response in breast cancer patients. The system was evaluated using a dataset that included **medical imaging data**, **clinical data**, and **genomic data**, and the performance was assessed through various evaluation metrics such as **accuracy**, **precision**, **recall**, **F1-score**, and **AUC** (Area Under the Curve).

1. Experimental Setup

The MM-CRNet model was implemented using the **PyTorch** framework. The dataset consisted of:

Medical Imaging: Mammogram and MRI scans of breast cancer patients.

Clinical Data: Patient demographics (age, gender), treatment history, tumor size, and chemotherapy regimen information.

Genomic Data: Gene expression profiles, mutation status, and copy number variations.

The dataset was split into **training** (70%), **validation** (15%), and **test** (15%) sets. The model was trained for 50 epochs with a batch size of 32. We used the **Adam optimizer** with a learning rate of 0.001 and applied **early stopping** to prevent overfitting.

Table 1: Experimental Setup

Data Type	Description
Medical Imaging	Mammogram and MRI scans of breast cancer patients
Clinical Data	Patient demographics, treatment history, tumor size
Genomic Data	Gene expression profiles, mutation status, copy number
Parameter	Value
Training Split	70%
Validation Split	15%
Test Split	15%
Batch Size	32
Learning Rate	0.001
Optimizer	Adam
Epochs	50

2. Quantitative Performance Evaluation

To evaluate the performance of MM-CRNet, we compared it to several baseline models, including a **CNN-based model** (using only imaging data), a **LSTM-based model** (using only clinical and genomic data), and a **traditional machine learning model** (such as Random Forest) combining all data modalities in a simplistic manner.

The evaluation metrics used are as follows:

Accuracy: Proportion of correct predictions out of all predictions.

Journal of Information Systems Engineering and Management
2025, 10(44s)
e-ISSN: 2468-4376
https://www.jisem-journal.com/
Research Article

Precision: Proportion of true positives among all positive predictions.

Recall: Proportion of true positives among all actual positives.

F1-score: Harmonic mean of precision and recall, providing a balance between the two.

AUC (Area Under the ROC Curve): Measures the ability of the model to discriminate between different classes (chemotherapy response).

Table 2 presents the performance of MM-CRNet compared to the baseline models

Model	Accuracy (%)	Precision (%)	Recall (%)	F1-Score (%)	AUC (%)
MM-CRNet (Proposed Model)	**88.6**	**89.3**	**87.5**	**88.4**	**92.7**
CNN-based Model (Image Only)	81.4	80.2	79.0	79.6	85.3
LSTM-based Model (Clinical & Genomic Data)	84.1	85.4	82.3	83.8	89.2
Random Forest (All Modalities)	85.3	84.0	84.5	84.2	88.5

MM-CRNet outperforms all baseline models across all evaluation metrics, showing that the combination of CNN for imaging data and LSTM for clinical/genomic data results in a better understanding of chemotherapy response.

The CNN-based model and LSTM-based model performed well but were limited by the modality they used, either focusing solely on images or temporal clinical/genomic data.

Random Forest provided decent performance but did not fully capitalize on the complex relationships between the multi-modal data sources.

3. Qualitative Analysis

In addition to quantitative metrics, we also evaluated the model qualitatively by inspecting the predictions on a subset of test images, clinical, and genomic data. **Figure 1** shows sample predictions for chemotherapy response, comparing the true label and predicted label for individual patients.

For images, the model accurately predicted the chemotherapy response in patients with both **positive** and **negative** outcomes based on tumor features such as size, shape, and texture.

For clinical and genomic data, the model correctly identified patterns in the temporal changes of genomic markers and clinical data, such as tumor size reduction or stable disease status, helping to reinforce the prediction.

Journal of Information Systems Engineering and Management
2025, 10(44s)
e-ISSN: 2468-4376
https://www.jisem-journal.com/
Research Article

Table 3: Qualitative Analysis

Evaluation Criteria	Observation
Imaging Analysis	**Accurate response prediction based on tumor size, shape, and texture**
Clinical Data Analysis	**Correct pattern identification in temporal patient data**
Genomic Data Analysis	**Accurate identification of chemotherapy response based on molecular changes**
Overall Findings	
Metric	**MM-CRNet (Proposed Model)**
Accuracy Improvement (%)	**88.6 - 85.3 = 3.3**
Precision Improvement (%)	**89.3 - 84.0 = 5.3**
Recall Improvement (%)	**87.5 - 84.5 = 3.0**
F1-Score Improvement (%)	**88.4 - 84.2 = 4.2**
AUC Improvement (%)	**92.7 - 88.5 = 4.2**

4. Ablation Study

To better understand the contribution of each component of the system, we conducted an **ablation study**, systematically removing one modality at a time from the MM-CRNet model. The results are summarized in

Table4, which shows the performance drop when either medical imaging, clinical data, or genomic data is removed.

Table 4: summarised result

Model	**Accuracy (%)**	**Precision (%)**	**Recall (%)**	**F1-Score (%)**	**AUC (%)**
MM-CRNet (All Modalities)	88.6	89.3	87.5	88.4	92.7
Without Imaging Data	84.3	85.1	82.8	83.9	88.1
Without Clinical Data	85.2	85.7	84.0	84.8	88.3
Without Genomic Data	86.4	86.2	85.0	85.6	89.6

Without imaging data, the performance dropped, indicating that medical imaging provides critical spatial features that are not captured by clinical or genomic data alone.

Without clinical data, the performance was slightly lower but still good, showing that temporal changes in patient history and treatment are important for predictions.

Without genomic data, the system performed better than without imaging or clinical data, highlighting the importance of genomic markers in predicting chemotherapy response.

Journal of Information Systems Engineering and Management
2025, 10(44s)
e-ISSN: 2468-4376
https://www.jisem-journal.com/
Research Article

This ablation study shows the value of integrating all three modalities—imaging, clinical, and genomic data—for optimal performance.

The **MM-CRNet** model demonstrates significant improvements in predicting chemotherapy response compared to traditional methods, especially when using multi-modal data. The integration of **medical imaging**, **clinical**, and **genomic** data allows the model to learn more comprehensive representations of the tumor and the patient's response to chemotherapy. The use of CNN for spatial feature extraction from images and LSTM for temporal feature extraction from clinical/genomic data results in a system capable of handling complex and varied data sources. The **high AUC** and **F1-score** indicate that the model is particularly effective in classifying chemotherapy responders and non-responders. The **ablation study** further confirms the importance of multi-modal data in improving prediction accuracy.

In this study, we proposed **MM-CRNet**, a novel model for predicting chemotherapy response in breast cancer patients, which combines convolutional and recurrent networks to process multi-modal data. Our experimental results show that MM-CRNet significantly outperforms baseline models, achieving higher accuracy and better overall prediction performance. The results highlight the importance of combining medical images, clinical data, and genomic data for making personalized predictions about chemotherapy response, which can assist clinicians in making more informed decisions about treatment strategies. The model demonstrates the potential of integrating deep learning techniques with multi-modal data sources for improving personalized healthcare outcomes.

Discussion

The MM-CRNet model presents a notable advancement in predicting chemotherapy response in breast cancer patients by seamlessly integrating multiple data modalities, including medical imaging, clinical records, and genomic profiles. The experimental results demonstrate that MM-CRNet outperforms traditional baseline models, achieving superior accuracy, precision, recall, and AUC scores. This improvement highlights the model's capability to extract spatial features from imaging data through CNNs while capturing temporal patterns in clinical and genomic data using LSTMs. By effectively merging these diverse features, MM-CRNet gains a more comprehensive understanding of chemotherapy response, enabling precise and personalized predictions.

Furthermore, the ablation study reinforces the significance of incorporating all three data modalities, showing that their combination leads to a substantial improvement in predictive performance. The model's adaptability to different data types underscores its potential for clinical application, making it a promising tool for enhancing decision-making in oncology. Beyond its impact on chemotherapy response prediction, MM-CRNet sets a foundation for integrating multi-modal deep learning in personalized medicine. However, to ensure its broader applicability and reliability in clinical settings, further validation with extensive and diverse datasets is necessary.

VII. CONCLUSION Bottom of Form

The proposed Multi-Modal Convolutional and Recurrent Network (MM-CRNet) improves chemotherapy response prediction in breast cancer patients by combining medical imaging, clinical data, and genetic information. The model successfully detects complex, multi-dimensional relationships that conventional approaches frequently miss by using long short-term memory (LSTM) networks to capture temporal patterns in clinical and genomic data and convolutional neural networks (CNNs) for spatial feature extraction from imaging data. Combining these many data sources improves the model's predictive power, resulting in higher accuracy, precision, recall, and AUC than with traditional models.

By offering a more complete picture of patient health, MM-CRNet shows great promise for practical use and helps oncologists make wise treatment decisions. The model's ability to integrate heterogeneous data sources underscores its utility in personalized treatment planning. However, further validation with larger, more diverse datasets is necessary to assess its generalizability across broader patient populations. Future research can explore incorporating additional modalities, such as proteomics and radiomics, and enhancing model interpretability to increase trust in AI-driven medical predictions. By bridging computational advancements with personalized medicine, MM-CRNet has the potential to optimize cancer treatment, minimize adverse effects, and contribute to improved patient outcomes.

Journal of Information Systems Engineering and Management
2025, 10(44s)
e-ISSN: 2468-4376
https://www.jisem-journal.com/
Research Article

REFERENCE

[1] **Cireşan, D. C., et al. (2013).** "Deep, big, simple neural networks for image classification." *Neural Networks*, 32, 188-195.
[2] **LeCun, Y., et al. (2015).** "Deep learning." *Nature*, 521(7553), 436-444.
[3] **Shin, H. C., et al. (2016).** "Deep Convolutional Neural Networks for Computer-Aided Detection: CNN Architectures, Dataset Characteristics, and Transfer Learning." *IEEE Transactions on Medical Imaging*, 35(5), 1285-1298.
[4] **Liu, Y., et al. (2017).** "Artificial intelligence in healthcare: Past, present and future." *Seminars in Cancer Biology*, 55, 59-69.
[5] **Esteva, A., et al. (2017).** "Dermatologist-level classification of skin cancer with deep neural networks." *Nature*, 542(7639), 115-118.
[6] **Sotiras, A., et al. (2017).** "Advances in medical image analysis." *Annual Review of Biomedical Engineering*, 19, 445-472.
[7] **Ronneberger, O., et al. (2015).** "U-Net: Convolutional Networks for Biomedical Image Segmentation." *Medical Image Computing and Computer-Assisted Intervention (MICCAI)*.
[8] **Vasan, N., et al. (2020).** "Machine learning and artificial intelligence in oncology: Current applications and future directions." *CA: A Cancer Journal for Clinicians*, 70(4), 276-297.
[9] **Topol, E. J. (2019).** "High-performance medicine: The convergence of human and artificial intelligence." *Nature Medicine*, 25(1), 44-56.
[10] **Liu, Y., et al. (2019).** "Multi-modal cancer prognosis prediction using deep learning." *IEEE Transactions on Biomedical Engineering*, 66(12), 3300-3309.
[11] **Ching, T., et al. (2018).** "Opportunities and obstacles for deep learning in biology and medicine." *Journal of the Royal Society Interface*, 15(141), 20170387.
[12] **Wang, X., et al. (2018).** "Multi-Scale Convolutional Neural Networks for Lung Nodule Classification." *IEEE Transactions on Biomedical Engineering*, 65(6), 1349-1359.
[13] **Greenspan, H., et al. (2016).** "Guest Editorial: Deep Learning in Medical Imaging." *Medical Image Analysis*, 36, 1-3.
[14] **Sahu, A., et al. (2020).** "Deep learning for survival prediction in breast cancer patients using histopathological images." *Computers in Biology and Medicine*, 121, 103770.
[15] **Liu, J., et al. (2020).** "A Deep Learning Model for Predicting Chemotherapy Response in Breast Cancer Patients." *IEEE Access*, 8, 113050-113057.
[16] **Chen, H., et al. (2016).** "Multi-scale deep learning for tissue-specific tumor detection and classification in breast cancer." *Proceedings of the International Conference on Machine Learning (ICML)*.
[17] **Srinivasan, S., et al. (2019).** "Artificial Intelligence in the Prediction of Chemotherapy Response: A Review." *Frontiers in Oncology*, 9, 1430.
[18] **Kermany, D. S., et al. (2018).** "Identifying Medical Diagnoses and Treatable Diseases by Image-Based Deep Learning." *Cell*, 172(5), 1122-1131.
[19] **Zhou, Z., et al. (2020).** "Deep learning for breast cancer prognosis prediction with multi-modal data: A comparative study." *Artificial Intelligence in Medicine*, 102, 101766.
[20] **Liu, S., et al. (2019).** "Genomic and imaging data fusion for the prediction of chemotherapy response in breast cancer." *Bioinformatics*, 35(19), 3471-3478.
[21] **Wang, L., et al. (2019).** "Prediction of breast cancer chemotherapy response with a deep learning model combining histopathology and genomics." *IEEE Journal of Biomedical and Health Informatics*, 23(4), 1679-1687.
[22] **Zhu, X., et al. (2019).** "Multi-view learning for predicting breast cancer recurrence." *IEEE Transactions on Neural Networks and Learning Systems*, 30(12), 3917-3929.
[23] **Han, S., et al. (2021).** "A multi-modal deep learning approach to predict breast cancer treatment response using histopathology and radiology data." *Journal of Medical Imaging*, 8(3), 034502.
[24] **Yu, L., et al. (2020).** "Combining multi-modal data with deep learning to predict chemotherapy response in breast cancer patients." *BMC Bioinformatics*, 21(1), 345.

Journal of Information Systems Engineering and Management
2025, 10(44s)
e-ISSN: 2468-4376
https://www.jisem-journal.com/

Research Article

[25] **Zhang, Y., et al. (2021).** "Deep learning for predicting breast cancer chemotherapy response using clinical, genomic, and radiological data." *Artificial Intelligence in Medicine*, 110, 101961.